文摘
Guidelines recommend endocrine therapy (ET) as first-line treatment for HER2-negative luminal-like metastatic breast cancer. In daily practice, chemotherapy (CT) is often used also outside of life-threatening disease. According to real life data of this study, clinicians preferred first-line CT in 38% of patients. Age and site of metastases influenced choice of first-line strategy (CT vs. ET). CT did not improve outcome compared to ET, as first-line treatment for HER2-negative luminal-like metastatic breast cancer.